Allworth Financial LP Buys 3,222 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Allworth Financial LP lifted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 50.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,582 shares of the company’s stock after purchasing an additional 3,222 shares during the period. Allworth Financial LP’s holdings in Takeda Pharmaceutical were worth $124,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in TAK. FMR LLC raised its stake in shares of Takeda Pharmaceutical by 10.9% during the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after purchasing an additional 286,052 shares in the last quarter. Stifel Financial Corp raised its stake in Takeda Pharmaceutical by 103.9% in the 3rd quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock valued at $6,266,000 after acquiring an additional 224,594 shares during the period. Summit Global Investments raised its stake in Takeda Pharmaceutical by 86.0% in the 3rd quarter. Summit Global Investments now owns 415,558 shares of the company’s stock valued at $5,909,000 after acquiring an additional 192,143 shares during the period. Crossmark Global Holdings Inc. raised its stake in Takeda Pharmaceutical by 284.9% in the 4th quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock valued at $2,787,000 after acquiring an additional 155,795 shares during the period. Finally, Van ECK Associates Corp raised its stake in Takeda Pharmaceutical by 6.6% in the 3rd quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock valued at $30,149,000 after acquiring an additional 134,407 shares during the period. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Up 1.6 %

TAK opened at $14.08 on Monday. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08. The stock’s fifty day simple moving average is $13.29 and its 200 day simple moving average is $13.88. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock has a market cap of $44.78 billion, a PE ratio of 35.19, a price-to-earnings-growth ratio of 0.24 and a beta of 0.51.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.